Lipocine (NASDAQ:LPCN) versus Pyxis Oncology (NASDAQ:PYXS) Financial Analysis

Pyxis Oncology (NASDAQ:PYXSGet Free Report) and Lipocine (NASDAQ:LPCNGet Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability and institutional ownership.

Profitability

This table compares Pyxis Oncology and Lipocine’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pyxis Oncology N/A -38.34% -30.01%
Lipocine N/A -38.58% -35.28%

Volatility & Risk

Pyxis Oncology has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, Lipocine has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500.

Insider and Institutional Ownership

39.1% of Pyxis Oncology shares are owned by institutional investors. Comparatively, 9.1% of Lipocine shares are owned by institutional investors. 9.8% of Pyxis Oncology shares are owned by company insiders. Comparatively, 6.1% of Lipocine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Pyxis Oncology and Lipocine”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pyxis Oncology N/A N/A -$73.79 million ($1.24) -2.83
Lipocine $4.80 million 6.02 -$16.35 million ($1.71) -3.16

Lipocine has higher revenue and earnings than Pyxis Oncology. Lipocine is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Pyxis Oncology and Lipocine, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pyxis Oncology 0 0 8 0 3.00
Lipocine 0 0 1 0 3.00

Pyxis Oncology presently has a consensus target price of $9.00, suggesting a potential upside of 156.41%. Lipocine has a consensus target price of $10.00, suggesting a potential upside of 85.19%. Given Pyxis Oncology’s higher probable upside, research analysts clearly believe Pyxis Oncology is more favorable than Lipocine.

Summary

Pyxis Oncology beats Lipocine on 9 of the 11 factors compared between the two stocks.

About Pyxis Oncology

(Get Free Report)

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

About Lipocine

(Get Free Report)

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.